摘要
目的:比较齐拉西酮与奥氮平治疗女性精神分裂症的疗效及安全性。方法:采用随机、单盲对照的方法,将80例女性精神分裂症患者随机分为两组,每组各40例,分别使用齐拉西酮和奥氮平对照治疗8周,采用阳性症状与阴性症状(PANSS)评定疗效,采用副反应量表(TESS)评定副反应。结果:两组疗效相当,但齐拉西酮组较奥氮平组引起的不良反应更少,对患者的体重无显著性影响,不易引起嗜睡。结论:齐拉西酮是一种安全有效的抗精神病药,较适合女性精神分裂症患者的治疗。
Objective： To compare the clinical efficacy and safety of ziprasidone and olanzapine in the treatment of female schizophenia. Method： 80 cases with female schizophrenia were divided randomly into two groups by single blind contrast.Each group with 40 cases, compare the use of ziprasidone and olanzapine in the treatment for 8 weeks.Positive and Negative syndrome scale （ PANSS ） was used to assess the efficacy, side effects scale （ TESS ） was used to assess adverse reactions.Result： There was significant curative effect of two groups.Bat the ziprasidone group cause less adverse reactions than the olanzapine group, with no significant effect on weight of patients, not easy to cause sleepiness.Conclusion： Ziprasidone is an effective and safe antipsychotic drug, more suitable for treatment of female patients with schizophrenia.
出处
《中国医学创新》
CAS
2013年第23期15-16,共2页
Medical Innovation of China
基金
2012年江西省宜春市课题(JXYC2012KSB0034)
